Best Life Sciences Tech Companies in Paris, France
The 45 best Life Sciences Tech companies in Paris, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Owkin.
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in Paris
| # | Company | Last round | Disclosed funding | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AdClin Provider of software products and services to help streamline the processing of clinical data | — | — | Unfunded | 2 | Thierry Lambert CEO | — | — | — |
| 2 | AgiLab Platform for management of scientific information | — | — | Unfunded | 11 | Joachim Mohamed Ndiaye CEO | WordPressMySQLPHP+31 | — | — |
| 3 | AgileBio IT solutions for labs, R&D, biotech and pharma industries | — | — | Unfunded | 17 | — | — | — | 6 launchs |
| 4 | Aureus Sciences Knowledge Management Systems for drug discovery research | — | — | Acquired | 4 | Jason Theodosiou ex-CEO | — | — | — |
| 5 | Blazar Developer of integrative bioinformatic platform | — | — | Funding Raised | 3 | Dora Sabino Co-Founder & CEO | — | — | — |
| 6 | Clinical Trials Mobile Application Technology platform for clinical trial recruitment | — | — | Funding Raised | — | Yoram Bouhnik Founder | — | — | — |
| 7 | DeltaWave Provider of automated deep learning technology for accelerating scientific discovery | — | — | Funding Raised | — | Ahmet Celebi Co-Founder | — | — | — |
| 8 | Euris CRM and CLM solutions for life sciences industry. | — | — | Unfunded | 51 | — | WordPressMySQLPHP+8 | — | — |
Top 12 Life Sciences Tech companies in Paris
#1
Owkin 🦄Series B · Paris, Ile de France · founded 2016 · 47 employees$321.1Mraised▾
AI generative biology company to create the new standard of biology reasoning. The company is creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. It is building the operating system for biology a platform in general-purpose biology intelligence.
- Mar 2026Series B$33M
- Jan 2023Grant (prize money)$216.4K
- Jun 2022Series B$80M
- Nov 2021Series B$180M
#2
Series A · Paris, Ile de France · founded 2019 · 60 employees$62.7Mraised▾
Provider of an AI and quantum physics to discover therapeutic molecules. The software uses AI-Based technology for screening different small molecules, knowing its physical properties helping in upstream processing and drug discovery. The software also helps in determining therapeutic targets responsible for particular diseases.
- Apr 2025Grant (prize money)$7.4M
- Dec 2024Series A$40.1M
- Jan 2024Series A$32.5M
- Oct 2022Series A$29.1M
#3
Series A · Paris, Ile de France · founded 2024$35Mraised▾
Developer of AI foundation model to transform biological research. The company's model would integrate different scales of biological data, from molecules to cells to tissues, to reveal new insights. It fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- Jan 2025Series A$41M
- Feb 2024Seed$35M
#4
Series B · Paris, Ile de France · founded 2018 · 35 employees$2.2Mraised▾
Primaa is a developer of AI-based software for automated and accurate histological diagnoses. The software is designed to assist pathology diagnosis. The product is based on image processing and artificial intelligence.
- Oct 2025Series B$8.2M
- Nov 2024Series A$5.4M
- Oct 2019Seed$2.2M
- Jul 2019Grant (prize money)$44.8K
#5
Seed · Paris, Ile de France · founded 2022 · 6 employees$7.7Mraised▾
Developer of bioproduction platform for drug discovery and development. It offers a platform that offers a technology that enables the yield of therapeutic proteins produced in mammalian cell factories by harnessing efficient processes from diverse organisms to revolutionize drug production.
- May 2025Seed$6.2M
- Jul 2023Grant (prize money)$84.3K
- Jul 2023Grant (prize money)$81.9K
- 2022Seed$1.3M
#6
Series A · Paris, Ile de France · founded 2019 · 10 employees$16.4Mraised▾
Provider of AI-based drug discovery and omics analysis tool for researchers. The company has developed tools that are AI-enabled for the process of drug discovery. The tool assists in provided insights for target protein for the drug for an individual patient. The tools use machine learning technology to identify molecular triggers for the drug and target identification. It has features to process biological data, tools for genomic screening, and more.
- Dec 2024Series A$10.5M
- Oct 2022Series A$5.9M
#7
Series A · Paris, Ile de France · founded 2016 · 49 employees$35.5Mraised▾
AI-based patient recruitment platform. The company offers an AI-based patient recruitment system, intending to accelerate recruitment by enabling data-driven site selection. It provides end-to-end personalized site selection by identifying potential sites, gathering information on each site, analyzing recruitment capabilities, modeling and optimizing recruitment, and more.
- Mar 2023Series A$20M
- Feb 2020Series A$14M
- Nov 2017Seed$1.5M
#8
Series E · Paris, Ile de France · founded 2008 · 70 employees$129.7Mraised▾
Developer of immunomodulatory drugs targeting cancer and immune diseases. The company develops drugs based on the ability to de-code the gut microbiome’s interaction with the immune system. The company has developed two technology platforms which include OncoMimics therapeutic cancer vaccines, and EndoMimics an oral bioactive to treat inflammatory and autoimmune diseases.
- Jun 2020Series E$52.3M
- Jan 2018Conventional Debt$48.1M
- Jan 2018Series D$38.5M
- Apr 2016Series C$16.4M
#9
Series A · Paris, Ile de France · founded 2012 · 68 employees$47Mraised▾
Provider of solutions for single-molecule genetic and epigenetic sequencing. The platform technology SIMDEQ (SIngle-molecule Magnetic Detection and Quantification), initially developed at École Normale Supérieure (ENS), exploits the biophysical properties of DNA and RNA to enable genetic and epigenetic sequencing. The DNA and RNA are converted into a 'hairpin' library that is immobilized on a magnetic bead. Under the influence of a magnetic field, these hairpins are 'zipped' and 'unzipped'.
- Dec 2021Series A$34.5M
- Oct 2021Grant (prize money)$115.6K
- Nov 2018Grant (prize money)$2.3M
- Dec 2016Grant (prize money)$52.7K
#10
Series A · Paris, Ile de France · founded 2016 · 55 employees$16.3Mraised▾
Iktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms.
- Mar 2023Series A$16.3M
#11
Seed · Paris, Ile de France · founded 2021$2.1Mraised▾
Digital clinical data and trial management tool for doctors and researchers. The company has developed software that assists professionals to manage clinical trial documents and patient information. It can be used for trial recruitment and other clinical processes.
- Apr 2024Seed$2.1M
#12
Series A · Paris, Ile de France · founded 2019 · 29 employees$10.2Mraised▾
Provider of drug discovery and development platform. The platform utilizes AI technology to predict and identify drug candidate molecules for therapeutic purposes.
- Sep 2022Series A$10.1M
- 2022Seed$500K
- Jul 2019Grant (prize money)$44.8K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Paris is moving
A read on the academic research around Biotechnology in Paris — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 143 papers.
- AgroParisTech36
- Université Paris-Saclay33
- Université Paris Cité19
- Assistance Publique – Hôpitaux de Paris17
- CEA Paris-Saclay13
- Gene4
- Genome4
- Cell culture3
- DNA damage3
- Mutation3
- Disease1→3
- Selection (genetic algorithm)3
- Antibiotic resistance3
- Interferon3
- Food science3
- Gene3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.